| New Apoptosis-Targeting Drug Gets B Cells, Spares Platelets | | Researchers have developed an experimental drug, ABT-199, that interferes with anti-apoptotic proteins. Unlike its precursor navitoclax, though, ABT-199 does not interfere with platelet function. The rationale for the therapeutic targeting of apoptosis, or programmed cell death, to treat cancer, is not hard to understand. Find out the details. |  |
- Why the FDA's focus on breakthrough meds is good news
 The pharmaceutical industry's focus will shift toward more groundbreaking, innovative medicines because of the Breakthrough Therapy Designation, the FDA's new regulatory incentive structure, Luke Timmerman writes. The emphasis on breakthrough drugs, together with the high number of drug approvals last year, is a positive development for drugmakers and patients, he writes. Xconomy (1/14)       - GSK submits diabetes drug albiglutide to FDA review
GlaxoSmithKline has applied to the FDA for approval to market albiglutide, an experimental weekly drug for diabetes. Albiglutide belongs to a class of drugs called GLP-1 agonists that includes Novo Nordisk's Victoza. GSK plans to submit the drug for approval in Europe as well. Reuters (1/14) - Evaluate early-stage assets in pipeline, pharma expert says
It is important to analyze a pharmaceutical company's entire pipeline, not just its drugs in late-stage trials, says John LaMattina, a former Pfizer R&D president and senior partner at PureTech Ventures. The information will indicate a company's therapeutic priority areas and strategies. He says some drug companies are very transparent with information about their early-stage assets. Forbes (1/14)  | Earn 30,000 American Airlines AAdvantage® Bonus Miles*
• Your first eligible checked bag is free for you and up to 4 traveling companions*
• Priority Boarding — Enjoy an enhanced boarding experience*
• Access to a CitiBusiness 24-hour Personal Business Assistant to help with travel, hotel and dining arrangements and more
*Learn more. |
  | Company & Financial News |  |  | | | Global Developments | | | | - EU expands approval of Janssen-Cilag's prostate cancer drug Zytiga
The European Commission approved the use of Janssen-Cilag's Zytiga, or abiraterone acetate, in combination with prednisolone or prednisone, for patients with metastatic castration-resistant prostate cancer who do not respond to androgen deprivation and for whom chemotherapy is not indicated. The drug's approval in the U.S. was expanded recently to include men with metastatic castration-resistant prostate cancer before chemotherapy. PharmaTimes (U.K.) (1/14)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
- European agency publishes data on Monsanto's biotech corn
The European Food Safety Authority has made all data on Monsanto's biotech corn NK603 available to the public online as part of the agency's commitment to "further enhance transparency in its decision-making processes." The move "will make the conclusions of risk assessments even stronger when ensuring public health protection and further build confidence in EFSA's work," EFSA official Catherine Geslain-Laneelle said. Fox Business/Dow Jones Newswires (1/14), FoodNavigator (1/14)  |
Dell has your IT wish list covered. Desktops, laptops and accessories. Save up to 35% on the latest technology for your medical practice. This touch-enabled 12" convertible laptop combines the fun of a Windows 8 touch tablet with the power and productivity of an Ultrabook™. Shop Now. |
 | Industrial & Environmental | | | | - Analysis: Biofuel industry could turn waste into profit
As the prices of traditional feedstocks continue to rise, more biofuel developers are looking into the potential of municipal solid waste, according to a white paper from Renewable Waste Intelligence. Building advanced biofuel plants in proximity to waste processing facilities could bring down feedstock costs, the paper stated. DomesticFuel.com (1/14) | News from BIO | | | | - Ship with FedEx
FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program.
| SmartQuote | | | |  | If you can't write your idea on the back of my calling card, you don't have a clear idea."
--David Belasco,
American theatrical producer, director and playwright  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Monday, January 14, 2013
- Friday, January 11, 2013
- Thursday, January 10, 2013
- Wednesday, January 09, 2013
- Tuesday, January 08, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment